Hepatocellular carcinoma (HCC) — the most common form of primary liver cancer — presents a treatment challenge unlike almost any other solid tumor. The liver is simultaneously the target of treatment and one of the body’s most radiation-sensitive organs. The liver tolerates radiation poorly in aggregate, meaning that while individual tumors within it can often be treated effectively, the amount of liver tissue that can be safely irradiated is strictly limited. This constraint has historically made radiation therapy a secondary consideration for many liver cancer patients.
Proton therapy changes that calculation. By concentrating radiation dose within the tumor and minimizing dose to the surrounding liver parenchyma, proton therapy allows oncologists to treat liver tumors with doses that would be unsafe using conventional X-ray radiation — while preserving the functional liver tissue that patients need to survive.
The Challenge of Treating the Liver
Most liver cancer patients in the United States have underlying liver disease — cirrhosis from hepatitis B, hepatitis C, nonalcoholic fatty liver disease, or alcohol use. This means they begin treatment with reduced hepatic reserve, making the consequences of radiation-induced liver injury particularly severe. Even modest doses of whole-liver radiation can trigger radiation-induced liver disease (RILD) in patients with cirrhosis, a serious and sometimes fatal complication.
The standard local treatments for HCC — surgical resection, ablation, and transarterial chemoembolization (TACE) — are limited by tumor size, location, vascular invasion, and the overall condition of the liver. For tumors that cannot be resected or ablated, and for patients who have exhausted or failed prior locoregional therapies, radiation therapy — specifically proton therapy — offers a meaningful alternative.
How Proton Therapy Solves the Liver Problem
The physics of proton therapy are particularly well suited to liver cancer. Protons deposit their energy at a defined depth — the Bragg Peak — and stop. Unlike X-rays, they do not irradiate tissue beyond the tumor. In the liver, this translates directly into liver-sparing: the tumor receives the prescribed dose, and the majority of the uninvolved liver is spared from significant radiation exposure.
Using Pencil Beam Scanning (PBS) technology, our team can conform the proton dose tightly around the tumor, even accounting for respiratory motion. The liver moves with every breath, and modern proton systems address this with respiratory gating and motion management techniques that ensure the beam tracks the tumor through the breathing cycle.
What the Evidence Shows
The clinical evidence for proton therapy in HCC has grown substantially over the past decade. A prospective phase 2 trial published in JAMA Oncology (Bush et al.) demonstrated 2-year local control rates of approximately 94% for unresectable HCC treated with proton therapy. Studies from Massachusetts General Hospital and other major proton centers have consistently reported excellent local control with low rates of treatment-related liver toxicity.
Notably, a 2019 randomized comparison published in the Journal of Clinical Oncology comparing proton therapy to TACE for Child-Pugh A HCC found equivalent local progression-free survival, with proton therapy demonstrating a significantly lower rate of worsening liver function — a critical finding for patients with cirrhosis. The American Cancer Society notes that proton therapy is increasingly used at specialized centers for liver cancer patients who are not candidates for surgery.
Candidates for Proton Therapy in Liver Cancer
Proton therapy is not appropriate for every liver cancer patient, but it is worth considering for several categories. Patients with unresectable HCC who have failed or are not candidates for TACE, patients with tumors near major bile ducts or vessels where ablation carries high risk, patients being bridged to liver transplantation who need effective local control, and patients with recurrent disease following prior locoregional therapy may all benefit from proton treatment.
Our radiation oncology team reviews liver cancer cases in coordination with hepatologists, transplant surgeons, and interventional radiologists to determine the most appropriate sequencing and integration of proton therapy within the overall treatment plan.
A Conversation Worth Having
If you or a loved one has been diagnosed with hepatocellular carcinoma and has been told that surgery or ablation is not an option, proton therapy deserves a place in the conversation. The technology that once made liver radiation too risky has been transformed by proton therapy’s precision.
Tennessee Oncology Proton Center offers proton therapy consultations for liver cancer patients throughout the region. Contact us to schedule an appointment and find out whether proton therapy is right for your situation.
